New hope for asthma and COPD patients: breakthrough treatment shows promise

The first new treatment for asthma attacks in 50 years could transform care for millions. A clinical trial co-authored by Dr Sanjay Ramakrishnan, researcher at the Institute for Respiratory Health, has shown that an injection can significantly reduce the need for further treatment during severe asthma and COPD attacks.

The trial, published in The Lancet Respiratory Medicine, found that the drug benralizumab is more effective than steroid tablets, cutting the need for additional treatment by 30%. This could be life-changing for those at risk of life-threatening asthma or COPD exacerbations, which claim millions of lives worldwide every year.

Dr Ramakrishnan started this research while working at the University of Oxford. “Treatment for COPD and asthma attacks has remained largely unchanged for decades,” he said. “This study shows we can deliver better outcomes for patients with targeted, effective care when they need it most.”

The ABRA trial, led by Professor Mona Bafadhel from King’s College London, tested benralizumab, a monoclonal antibody already used for severe asthma, during asthma and COPD flare-ups. Unlike traditional steroid tablets, which can cause serious side effects like diabetes and osteoporosis and often fail to prevent further attacks, the injection showed significant benefits. It reduced hospital visits, improved breathing symptoms, and enhanced quality of life for participants.

Dr Ramakrishnan, said the findings highlight the importance of targeted therapies. “It’s incredibly rewarding to be part of a study that has the potential to improve the lives of millions of people living with chronic respiratory conditions.”

The trial was a collaboration between leading researchers from institutions including the University of Oxford, King’s College London, and NHS Trusts in the UK.

Professor Bafadhel said the results could be “game-changing” for asthma and COPD care. “Treatment for exacerbations has not changed in over 50 years. This study shows that targeted therapy can make a real difference for people at high risk, improving their health and quality of life.”

Asthma and COPD exacerbations remain a major health burden, affecting millions globally and leading to significant costs for healthcare systems. The ability to administer benralizumab in emergency settings or GP clinics could revolutionise how these conditions are managed.

The study was supported by AstraZeneca UK Limited and highlights the importance of ongoing investment in respiratory health research. The findings are expected to spark discussions about updating treatment guidelines for asthma and COPD attacks worldwide.

Media contact:

RDM Marketing Consultants
Mobile- 0450613460